Mary Wilson
Well-known member
Journal of Clinical Virology
Available online 17 September 2023, 105584
https://doi.org/10.1016/j.jcv.2023.105584
Elisabetta Schiaroli [SUP]1[/SUP], Anna Gidari [SUP]1[/SUP], Giovanni Brachelente [SUP]2[/SUP], Giulia Bicchieraro [SUP]3[/SUP], Roberta Spaccapelo [SUP]4[/SUP], Sabrina Bastianelli [SUP]1[/SUP], Sara Pierucci [SUP]1[/SUP], Chiara Busti [SUP]1[/SUP], Carlo Pallotto [SUP]1[/SUP], Lisa Malincarne [SUP]1[/SUP], Barbara Camilloni [SUP]6[/SUP], Flavio Falcinelli [SUP]5[/SUP], Giuseppe Vittorio De Socio [SUP]1[/SUP], Alfredo Villa [SUP]2[/SUP], Antonella Mencacci [SUP]6[/SUP], Daniela Francisci [SUP]1 [/SUP]Show more
Abstract
Background
Tixagevimab-cilgavimab has been approved as primary pre-exposure prophylaxis in immunocompromised patients as support or replacement for vaccination, even though the Omicron variant of concern (VOC) was spreading at the time.
Objectives
The aim of our study was to evaluate the post-injection neutralising activity (NT[SUB]90[/SUB]-Abs titre) against the Omicron BA.5 variant in fully vaccinated immunocompromised patients.
Study design
NT[SUB]90[/SUB]-Abs titres against BA.5 and 20A.EU1 as well as anti-spike, and anti-receptor-binding domain IgG were evaluated 0, 14, and 30 d after tixagevimab-cilgavimab administration. The primary end point was NT[SUB]90[/SUB]-Abs titres ≥ 80 against BA.5 in ≥ 25% of patients, and the secondary end point was NT[SUB]90[/SUB]-Abs titres ≥ 1280 against 20A.EU1 in >50% of patients on day 14.
Results
At baseline, 35.2%, 37.02%, and 32.5% of booster vaccinated patients exhibited undetectable levels of anti-S and anti-RBD IgG antibodies such as NT[SUB]90[/SUB]-Abs titres against A20.EU1. Moreover, 35 patients (61.5%) had undetectable NT[SUB]90[/SUB]-Abs titres against BA.5. On day 14, IgG anti-S and anti-RBD levels were 3880 BAU/mL and 776.6 AU/mL, respectively. Only 12.5% of patients met a NT[SUB]90[/SUB]-Abs titres ≥ 80 against BA.5, whereas the median NT[SUB]90[/SUB]-Abs titre against 20A.EU1 was 1280. NT[SUB]90[/SUB]-Abs titres against BA.5 were 64-fold lower than those against A20.EU1. Four patients (7.5%) had a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the 3 months after treatment, all with a time gap between the booster vaccination and injection.
Conclusions
To date, tixagevimab-cilgavimab cannot be considered a substitute for vaccination but may be a useful supporting therapy if the recommended dose for pre-exposure prophylaxis is doubled.
https://www.sciencedirect.com/science/article/abs/pii/S138665322300207X?via=ihub
Available online 17 September 2023, 105584
https://doi.org/10.1016/j.jcv.2023.105584
Elisabetta Schiaroli [SUP]1[/SUP], Anna Gidari [SUP]1[/SUP], Giovanni Brachelente [SUP]2[/SUP], Giulia Bicchieraro [SUP]3[/SUP], Roberta Spaccapelo [SUP]4[/SUP], Sabrina Bastianelli [SUP]1[/SUP], Sara Pierucci [SUP]1[/SUP], Chiara Busti [SUP]1[/SUP], Carlo Pallotto [SUP]1[/SUP], Lisa Malincarne [SUP]1[/SUP], Barbara Camilloni [SUP]6[/SUP], Flavio Falcinelli [SUP]5[/SUP], Giuseppe Vittorio De Socio [SUP]1[/SUP], Alfredo Villa [SUP]2[/SUP], Antonella Mencacci [SUP]6[/SUP], Daniela Francisci [SUP]1 [/SUP]Show more
Abstract
Background
Tixagevimab-cilgavimab has been approved as primary pre-exposure prophylaxis in immunocompromised patients as support or replacement for vaccination, even though the Omicron variant of concern (VOC) was spreading at the time.
Objectives
The aim of our study was to evaluate the post-injection neutralising activity (NT[SUB]90[/SUB]-Abs titre) against the Omicron BA.5 variant in fully vaccinated immunocompromised patients.
Study design
NT[SUB]90[/SUB]-Abs titres against BA.5 and 20A.EU1 as well as anti-spike, and anti-receptor-binding domain IgG were evaluated 0, 14, and 30 d after tixagevimab-cilgavimab administration. The primary end point was NT[SUB]90[/SUB]-Abs titres ≥ 80 against BA.5 in ≥ 25% of patients, and the secondary end point was NT[SUB]90[/SUB]-Abs titres ≥ 1280 against 20A.EU1 in >50% of patients on day 14.
Results
At baseline, 35.2%, 37.02%, and 32.5% of booster vaccinated patients exhibited undetectable levels of anti-S and anti-RBD IgG antibodies such as NT[SUB]90[/SUB]-Abs titres against A20.EU1. Moreover, 35 patients (61.5%) had undetectable NT[SUB]90[/SUB]-Abs titres against BA.5. On day 14, IgG anti-S and anti-RBD levels were 3880 BAU/mL and 776.6 AU/mL, respectively. Only 12.5% of patients met a NT[SUB]90[/SUB]-Abs titres ≥ 80 against BA.5, whereas the median NT[SUB]90[/SUB]-Abs titre against 20A.EU1 was 1280. NT[SUB]90[/SUB]-Abs titres against BA.5 were 64-fold lower than those against A20.EU1. Four patients (7.5%) had a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the 3 months after treatment, all with a time gap between the booster vaccination and injection.
Conclusions
To date, tixagevimab-cilgavimab cannot be considered a substitute for vaccination but may be a useful supporting therapy if the recommended dose for pre-exposure prophylaxis is doubled.
https://www.sciencedirect.com/science/article/abs/pii/S138665322300207X?via=ihub